195 related articles for article (PubMed ID: 19080728)
1. Apolipoprotein A-I mimetic peptides.
Van Lenten BJ; Wagner AC; Anantharamaiah GM; Navab M; Reddy ST; Buga GM; Fogelman AM
Curr Atheroscler Rep; 2009 Jan; 11(1):52-7. PubMed ID: 19080728
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
3. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
[TBL] [Abstract][Full Text] [Related]
5. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
6. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
[TBL] [Abstract][Full Text] [Related]
7. Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.
Van Lenten BJ; Navab M; Anantharamaiah GM; Buga GM; Reddy ST; Fogelman AM
Curr Opin Investig Drugs; 2008 Nov; 9(11):1157-62. PubMed ID: 18951294
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice.
Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM
Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.
Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical utility of high-density lipoprotein-mimetic peptides.
Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
Curr Opin Lipidol; 2006 Aug; 17(4):440-4. PubMed ID: 16832169
[TBL] [Abstract][Full Text] [Related]
11. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
Ou J; Wang J; Xu H; Ou Z; Sorci-Thomas MG; Jones DW; Signorino P; Densmore JC; Kaul S; Oldham KT; Pritchard KA
Circ Res; 2005 Nov; 97(11):1190-7. PubMed ID: 16224061
[TBL] [Abstract][Full Text] [Related]
12. The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.
Di Bartolo BA; Vanags LZ; Tan JT; Bao S; Rye KA; Barter PJ; Bursill CA
Lipids Health Dis; 2011 Nov; 10():224. PubMed ID: 22128776
[TBL] [Abstract][Full Text] [Related]
13. Human apolipoprotein A-I exerts a prophylactic effect on high-fat diet-induced atherosclerosis via inflammation inhibition in a rabbit model.
Li J; Wang W; Han L; Feng M; Lu H; Yang L; Hu X; Shi S; Jiang S; Wang Q; Ye L
Acta Biochim Biophys Sin (Shanghai); 2017 Feb; 49(2):149-158. PubMed ID: 28069582
[TBL] [Abstract][Full Text] [Related]
14. The effect of HDL mimetic peptide 4F on PON1.
Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
[TBL] [Abstract][Full Text] [Related]
15. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice.
Weihrauch D; Xu H; Shi Y; Wang J; Brien J; Jones DW; Kaul S; Komorowski RA; Csuka ME; Oldham KT; Pritchard KA
Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1432-41. PubMed ID: 17496220
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.
McGrath KC; Li X; Twigg SM; Heather AK
PLoS One; 2020; 15(1):e0226931. PubMed ID: 31914125
[TBL] [Abstract][Full Text] [Related]
17. ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta.
Vaziri ND; Bai Y; Yuan J; Said HL; Sigala W; Ni Z
Am J Nephrol; 2010; 32(3):201-211. PubMed ID: 20639628
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
[TBL] [Abstract][Full Text] [Related]
19. D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1.
Xie Q; Zhao SP; Li F
Tohoku J Exp Med; 2010 Mar; 220(3):223-8. PubMed ID: 20208418
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats.
Peterson SJ; Husney D; Kruger AL; Olszanecki R; Ricci F; Rodella LF; Stacchiotti A; Rezzani R; McClung JA; Aronow WS; Ikehara S; Abraham NG
J Pharmacol Exp Ther; 2007 Aug; 322(2):514-20. PubMed ID: 17488882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
